Analyze Contracts Like a Lawyer - Wordsmith’s First Pass Unlocks Legal Insight for Everyone
“Contracts often hold up business because legal teams are stretched too thin,” said Ross McNairn, CEO of Wordsmith. “First Pass allows anyone from the legal, commercial or other teams to quickly identify risks and key terms, helping move things forward.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241108164624/en/
Wordsmith's First Pass lets you review contracts in minutes, not hours. (Graphic: Business Wire)
This is a glimpse at the future of legal AI agents. Taking a very specific task end-to-end and making it trivial for anyone to trigger.
Try It for Free
Users can access First Pass for free by creating an account at wordsmith.ai and then uploading the relevant agreement to the web, or simply email standard agreements—like NDAs—to nda@wordsmith.ai. Over the coming weeks, Wordsmith will be expanding this to many other agreement types.
End-to-End AI Analysis—More Than Just Contracting
What makes First Pass revolutionary is its AI-powered ability to handle the full process: from opening the email to classifying the document, analyzing key terms, flagging risks, marking up agreements, and preparing a follow-up—all without the need for special software. This makes it the fastest and simplest tool available for contract analysis.
Customizable for Your Team's Needs
For businesses that need tailored contract checks, Wordsmith provides advanced customization options. Teams can configure First Pass to flag specific risks or terms, with the option for legal teams to approve reviews where needed.
More Than Just Contract Review—A Suite of Productivity Tools
First Pass is just one of many powerful tools offered by Wordsmith. The platform also includes helpful features like full document translation for contracts in multiple languages, allowing businesses to handle international agreements with ease. Additionally, Wordsmith offers tools to auto-draft documents, respond to repetitive queries, and streamline workflows for maximum efficiency.
A New Era of Simple, Effective Contract Analysis
Tara Haig, the General Counsel from Multiverse, a European Unicorn, commented, “It understands nuanced legal language spread across different sections of agreements. The level of accuracy and detail is truly impressive.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20241108164624/en/
Contacts
Harris Grant | press@wordsmith.ai
General Media Info: Visit Wordsmith Press and Media -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.wordsmith.
ai%2Fpress-and-media&esheet=54148805&newsitemid=20241108164624&lan=en-US&anchor=
Wordsmith+Press+and+Media&index=2&md5=b70031d15cdaca76e9b30bd30c6204f7
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research7.11.2024 22:01:00 CET | Press Release
Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies. Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio’s portfolio of technology and services complements Maravai’s nucleic acid production services and is expected to provide customers with significant benefits as they bring new and innovative therapies to patients in need. “Officinae Bio’s uniqu
IonQ to Increase Performance and Scale of Quantum Computers with Photonic Integrated Circuits in Collaboration with imec7.11.2024 22:00:00 CET | Press Release
IonQ (NYSE: IONQ), a leader in the quantum computing industry, announced today that it is developing photonic integrated circuits (PICs) and chip-scale ion trap technology for trapped ion quantum computing in partnership with imec, a world-renowned R&D center in nanoelectronics and digital technologies. By optimizing the design, production, and integration of chip-scale photonic devices and ion traps for scalable and high-performance quantum computers, the developments aim to push the boundaries of quantum computing performance. Traditional trapped ion quantum computing approaches rely on bulk optics for laser light modulation, delivery, and photon collection. By moving traditional bulk optical components into integrated photonic devices, IonQ aims to reduce overall hardware system size and cost, increase qubit count, and improve system performance and robustness. Chip-scale optical technologies and IonQ’s tight integration with imec’s trap manufacturing and packing are expected to ope
BM3EAC Corp. Termination of Discussions Regarding Proposed Business Combination With Arkon Energy7.11.2024 18:29:00 CET | Press Release
BM3EAC Corp. (the “Company”), a shell company incorporated under the laws of the Cayman Islands as an exempted company with limited liability and listed on Euronext Amsterdam, the regulated market operated by Euronext Amsterdam N.V., hereby announces the termination of the discussions with Arkon Energy Ohio LLC (now Arkon Energy US Holdco LLC) (“Arkon”) regarding a potential transaction, including a business combination, initially announced on 21 February 2024 (the “Potential Business Combination”). After careful consideration, the Company and Arkon have determined that the current market conditions are not conducive to proceeding with the Potential Business Combination. IMPORTANT INFORMATION This press release may contain information that qualifies or may have qualified as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or s
Brenus Pharma Publishes Promising Proof of Concept Results of their Therapeutic Platform in the Scientific Frontiers in Oncology Journal. (1)7.11.2024 18:00:00 CET | Press Release
Brenus Pharma has announced the publication of a scientific article describing its new “off-the-shelf” cancer treatment in “Frontiers in Oncology” Section Cancer Immunity and Immunotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241107407975/en/ Brenus’ platform mimics patients’ relapsing conditions in lab, to educate the immune system against tumors evolution with the largest panel of multi-specific targets available. Its lead candidate is a proteomic-guided immunotherapy, designed to treat patients with advanced or metastatic CRC. Results show that the murine surrogate treatment inhibits tumor growth and improves survival of treated mice bearing tumors. It has also shown efficacy in a PD1-resistant model, with an increased infiltration of CD8+T cells in cold tumors, associated with strong safety data. Indeed, the treatment’s in vitro exposition to standards of careinduces the expression of cancer-related proteins l
Sandvine Announces Comprehensive Restructuring Transaction as Part of Ongoing Business Realignment7.11.2024 15:35:00 CET | Press Release
Sandvine Corporation and certain of its affiliates and subsidiaries (“Sandvine” or the “Company”) today announced that it has commenced proceedings under the Companies’ Creditors Arrangement Act (“CCAA”) in the Ontario Superior Court of Justice (Commercial List) and is in the process of commencing a companion recognition proceeding under Chapter 15 of Title 11 of the United States Code (“Chapter 15”) in the United States Bankruptcy Court for the Northern District of Texas (Dallas Division) in order to implement a comprehensive restructuring transaction. On October 2, 2024, the Company entered into a Restructuring Support Agreement (“RSA”) with over 97% of its secured lenders, who are also current shareholders of the Company (“Investors”), to implement a transaction that would result in, among other things, the conversion of the Company’s legacy funded debt obligations into equity and the funding of the Company through a new super senior loan facility under which the Investors provide n
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom